Omeros | OMER - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Adma Biologics USD 80.75M 8.07M 2026-03
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
BioMarin Pharmaceutical USD 713.42M 142.21M 2026-06
Cytokinetics USD 23.03M 3.84M 2026-06
Gilead Sciences USD 6.8B 1.29B 2026-06
Heron Therapeutics USD 29.47M 3.17M 2025-12
Immunic 0 0 2025-03
Insmed USD 356.19M 99.73M 2026-06
Knight Therapeutics CAD 64.72M 8.91M 2025-12
MacroGenics USD 11.24M 19.87M 2026-03
Omeros USD -33.16M 18.52M 2024-06
Pacira USD 133.91M 7.27M 2026-06
Pfizer USD -248M 11.29B 2026-06
Rockwell Medical USD 4.55M 1.49M 2024-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
United Therapeutics USD 683.8M 35.7M 2026-06
Vertex Pharmaceuticals USD 2.84B 242.4M 2026-06